ClinicalTrials.gg
Status unknownNCT03942198Updated May 8, 2019

Oral Chinese Herbal Medicine for Psoriasis Vulgaris With Blood Stasis Syndrome

A Phase 2 interventional study of Taodan Granules and Taodan Granules Placebo in Psoriasis Vulgaris, sponsored by Shanghai Yueyang Integrated Medicine Hospital. Status unknown at 5 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-05-08.

Sponsored by Shanghai Yueyang Integrated Medicine Hospital · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified May 2019), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 13 studies in Psoriasis by Shanghai Yueyang Integrated Medicine Hospital — 6 open to participants now, 6 under way, none of them phase 3. Psoriasis · Shanghai Yueyang Integrated Medicine Hospital.

Started
2019
with 5 others
Phase 2
4 of 13
none open now
Registered
2nd of 13
by date

Among the 13 studies in Psoriasis by Shanghai Yueyang Integrated Medicine Hospital, this one is one of 6 that started in 2019, is one of 4 in phase 2, and was the 2nd registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 13 studies in Psoriasis by Shanghai Yueyang Integrated Medicine Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 174 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Psoriasis by Shanghai Yueyang Integrated Medicine Hospital, or all of them as a file.
02

Study summary

We designed this study as a multicenter, randomized, double blinded and placebo-controlled clinical trial. The aim of the study is to evaluate the clinical efficacy, safety and control of recurrence rate of psoriasis with blood stasis syndrome.

Read the detailed description

Psoriasis is a chronic, relapsing, inflammatory, multisystem disease characterized by infiltration of inflammatory cells, hyperplasia of epidermal keratinocytes, and abnormal differentiation. Latest data estimate that the prevalence of psoriasis in adults has increased to 11.43%, which shows that the control and treatment of psoriasis is still insufficient. Recent studies showed that traditional Chinese medicine (TCM) is one of the effective methods for the treatment of psoriasis. More and more evidences support the recognition of psoriasis not only affects the skin, but also suffers a chronic multisystem inflammation. In addition, blood-stasis accumulates in meridians, viscera and limbs to form a variety of syndromes with psoriasis for so long, which similar to many metabolic related diseases. Therefore, the method of promoting blood circulation and removing blood stasis has always been the focus of TCM treatment and prevention of psoriasis. This multicenter, randomized, double-blind, placebo-controlled trial will provide high-quality clinical evidences for evaluating the efficacy, safety and recurrence rate of Taodan granule, a representative prescription for the treatment of psoriasis with blood stasis syndrome, in the treatment of psoriasis.

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

Keywords

  • Plaque psoriasis
  • Promoting blood circulation for removing blood stasis
  • Randomized controlled trial
  • Taodan Granules
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Comply with the diagnostic criteria of Western medicine for psoriasis and the diagnostic criteria for TCM syndromes;
  2. Skin lesions involve ≤10% BSA (the lesions are mainly located in the trunk and/or limbs, palm/sole, face/scalp, vulva area is not included);
  3. Age between 18 and 65 years old;
  4. Those who voluntarily participate in the study and sign .

Exclusion criteria

Exclusion Criteria:

  1. Patients with erythrodermic, arthritic, pustular or punctate psoriasis;
  2. Other active skin diseases may affect the condition assessment;
  3. Received research drugs, biological agents and agents within 1 month;
  4. 2 weeks of treatment with topical , phototherapy, etc.;
  5. During severe, uncontrollable local or systemic acute or chronic infections;
  6. Patients with severe systemic diseases; or clinical test indicators in one of the following conditions: or aspartate aminotransferase increased by >1.5 times the ; creatinine increased by 1.5 times the upper limit of normal; blood routine indicators (white blood cell count) Any one of the red blood cell count, amount, and count) is below the lower limit of normal; or other laboratory abnormalities are judged by the investigator to be unsuitable for participation in the trial;
  7. A history of malignant tumors and patients with primary or secondary immunodeficiency and ;
  8. Such surgery will be required during major surgery or study during 8 weeks;
  9. Pregnant or lactating women;
  10. A person with a history of alcohol abuse, drug abuse or drug abuse;
  11. Have a history of serious mental illness or family history;
  12. Other reasons researchers believe that it is inappropriate to participate in this research.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
216 participants (estimated)

Study arms

  • Experimental
    Oral Chinese medicine

    Participants in experimental group will receive Taodan granule two times daily after meals three times per week for 8 weeks.

    Drug: Taodan Granules

  • Placebo comparator
    Oral Chinese medicine placebo

    Participants in placebo group will receive Taodan granule two times daily after meals three times per week for 8 weeks.

    Drug: Taodan Granules Placebo

Interventions

  • DrugDrugs, Chinese HerbalStudies of Drugs, Chinese HerbalDrugs, Chinese Herbal pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.

    Also known as: Chinese Herbal Medicine

  • DrugTaodan Granules Placebo

    Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.

    Also known as: Chinese Herbal Medicine

06

What researchers measure

Primary outcomes

  1. Psoriasis area and severity index (PASI)

    Psoriasis Area and Severity Index (PASI) involves grading psoriatic plaques based on erythema (E), infiltration (I), desquamation (D). Severity is graded from 0-4 for each criteria (0 - none, 1 - slight, 2 - moderate, 3 - severe, and 4 - very severe). The body is divided into 4 regions, head, upper extremities, trunk, and lower extremities, and for each region, the surface area involvement is graded on a 0-6 scale (0 - 0% involvement, 1 - \<10%, 2 - 10-\<30%, 3 - 30-\<50%, 4 - 50-\<70%, 5 - 70-\<90%, 6 - 90-100%).The highest potential PASI score is 72, with higher PASI scores indicating worse psoriasis.

    Time frame: Up to 56 days after treatment

Secondary outcomes

  1. Body surface area (BSA)

    The percentage of body surface area (BSA) involved in psoriasis is estimated by fingerprinting, where the entire palm of the patient represents approximately 1% of the total BSA. The number of handprints on psoriasis skin in a body part is used to determine the extent to which the body part is affected by psoriasis (%)

    Time frame: Up to 56 days after treatment

  2. Physician Global Assessment (PGA)

    Physician Global Assessment (PGA) is scored on a 5-point scale, reflecting a global consideration of the erythema (E), infiltration (I), desquamation (D) across all psoriatic lesions. It is calculated as follows: PGA score = (E + I + D) / 3, then the score needs to be rounded to the nearest whole number \[PGA scale: Clear (0) - Very Severe (5)\].

    Time frame: Up to 56 days after treatment

  3. Dermatology Life quality index(DLQI)

    The Dermatology Life Quality Index (DLQI) is a participant-reported questionnaire used to measure the health-related quality of life (QOL) of adults suffering from a skin disease. Scores range from 0-30, a higher score indicating a greater impact on a participant's quality of life.

    Time frame: Up to 56 days after treatment

  4. Patient-reported quality of life (PRQoL)

    Patient-reported quality of life (PRQoL) is used to assess the impact of psoriasis on individual social life. Scores range from 0-25, a higher score indicating a greater impact on a participant's social life.

    Time frame: Up to 56 days after treatment

  5. Visual Analogue Score (VAS)

    Visual Analog Scale (VAS) is used to measure lesion pruritus from 0 to 100 mm at eash visit (with 0 being no pruritis and 100 being maximum pruritis).

    Time frame: Up to 56 days after treatment

  6. TCM symptom score

    The TCM symptom score is used to assess changes in blood syndrome related symptoms during treatment.

    Time frame: Up to 56 days after treatment

07

Study locations

5 sites
  • Shijiazhuang Hospital of Traditional Chinese Medicine
    Shijiazhuang, Hebei, China
  • First Affiliated Hospital of Heilongjiang Chinese Medicine University
    Harbin, Heilongjiang, China
  • Affiliated hospital of jiangxi university of traditional Chinese medicine
    Nanchang, Jiangxi, China
  • Shanghai Yueyang Integrated Medicine Hospital
    Shanghai, Shanghai Municipality, China
  • Shanxi Provincial Hospital of Traditional Chinese Medicine
    Xi’an, Shanxi, China
08

References and documents

Publications

  • Ru Y, Yan XN, Yang SQ, Gong LP, Li LE, Chen J, Zhao YD, An YP, Huang G, Zhang JF, Yin QF, Wang RP, Li X, Li B. Oral Taodan granules for mild-to-moderate psoriasis vulgaris: protocol for a randomized, double-blind, multicenter clinical trial. Ann Transl Med. 2019 Sep;7(18):488. doi: 10.21037/atm.2019.09.05. PubMed 31700924 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2019; primary completion for Dec 2021, 30 months later.

Of 29 non-industry phase 2 interventional studies under Psoriasis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 43. This study's planned 30 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2019
First posted
May 8, 2019
StartEst.
Jun 1, 2019
Primary completionEst.
Dec 31, 2021
CompletionEst.
Dec 31, 2021
Last update
May 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03942198
Lead sponsor
Shanghai Yueyang Integrated Medicine Hospital
Collaborators
Shaanxi Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Shijiazhuang Hospital of Traditional Chinese Medicine, Heilongjiang University of Chinese Medicine
Responsible party
Sponsor
First posted
May 8, 2019
Start date
Jun 1, 2019 (estimated)
Primary completion
Dec 31, 2021 (estimated)
Completion
Dec 31, 2021 (estimated)
Last update
May 8, 2019

Study contacts

Bin Li
Contact
18930568129@163.com
0086-021-55981301
Jie Chen
Contact
dercj366@163.com
0086-021-65161782-3137
Jia Zhou
study chair · Department of dermatology, Shanghai Yueyang Integrated Medicine Hospital, Shanghai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Drugs, Chinese Herbal

Start the discussion